**Supplemental Digital Content 4.** Table that shows the adverse events

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Arm A** | | | |  | **Arm B** | | | |
|  |  | **Toxicity grade (n, %)** | | | |  | **Toxicity grade (n, %)** | | | |
|  |  | **All grade** | | **Grade ≥ 3** | |  | **All grade** | | **Grade ≥ 3** | |
| **During induction CapeOx (arm A only)** | | | | | | | | | | |
|  | | **(n=18)** | | | |  |  |  |  |  |
| **Hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Leucopenia | 4  4  -  2  0 | 22.2%  22.2%  -  11.1%  0% | 0  0  0  1  0 | 0%  0%  0%  5.6%  0% |  |  |  |  |  |
|  | Neutropenia |  |  |  |  |  |
|  | Febrile neutropenia |  |  |  |  |  |
|  | Thrombocytopenia |  |  |  |  |  |
|  | Anemia |  |  |  |  |  |
| **Non-hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Fatigue | 5  6  0  9  0  1 | 27.8%  33.3%  0%  50.0%  0%  5.6% | 0  0  0  0  0  0 | 0%  0%  0%  0%  0%  0% |  |  |  |  |  |
|  | Nausea |  |  |  |  |  |
|  | Diarrhea |  |  |  |  |  |
|  | Sensory neuropathy |  |  |  |  |  |
|  | Hand-foot syndrome |  |  |  |  |  |
|  | Anal pain |  |  |  |  |  |
| **During preoperative chemoradiotherapy with CapeOx (both arms A and B)** | | | | | | | | | | |
|  |  | **(n=15)** | | | |  | **(n=20)** | | | |
| **Hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Leucopenia | 1  3  -  4  2 | 6.7%  20.0%  -  26.7%  13.3% | 0  0  0  1  0 | 0%  0%  0%  6.7%  0% |  | 2  2  -  4  1 | 10.0%  10.0%  -  20.0%  15.0% | 0  0  0  0  0 | 0%  0%  0%  0%  0% |
|  | Neutropenia |  |
|  | Febrile neutropenia |  |
|  | Thrombocytopenia |  |
|  | Anemia |  |
| **Non-hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Fatigue | 5  3  6  5  1  4 | 33.3% | 0  0  1  0  0  0 | 0%  0%  6.7%  0%  0%  0% |  | 9  7  6  13  1  8 | 45.0%  35.0%  30.0%  65.0%  5.0%  40.0% | 0  0  2  0  0  0 | 0%  0%  10.0%  0%  0%  0% |
|  | Nausea | 20.0% |  |
|  | Diarrhea | 40.0% |  |
|  | Sensory neuropathy | 33.3% |  |
|  | Hand-foot syndrome | 6.7% |  |
|  | Anal pain | 26.7% |  |
| **During postoperative CapeOx** | | | | | | | | | | |
|  |  | **(n=14)** | | | |  | **(n=17)** | | | |
| **Hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Leucopenia | 6  6  -  6  0 | 42.9%  42.9%  -  42.9%  0% | 1  3  0  1  0 | 7.1%  21.4%  0%  7.1%  0% |  | 9  8  -  1  0 | 52.9%  47.1%  -  5.9%  0% | 0  2  0  0  0 | 0%  11.8%  0%  0%  0% |
|  | Neutropenia |  |
|  | Febrile neutropenia |  |
|  | Thrombocytopenia |  |
|  | Anemia |  |
| **Non-hematologic** | |  |  |  |  |  |  |  |  |  |
|  | Fatigue | 2  4  0  13  2  1 | 14.3% | 0  0  0  1  1  0 | 0%  0%  0%  7.1%  7.1%  0% |  | 4  6  2  13  3  3 | 23.5%  35.3%  11.8%  76.5%  17.6%  17.6% | 1  3  1  1  1  0 | 5.9%  17.6%  5.9%  5.9%  5.9%  0% |
|  | Nausea | 28.6% |  |
|  | Diarrhea | 0% |  |
|  | Sensory neuropathy | 92.9% |  |
|  | Hand-foot syndrome | 14.3% |  |
|  | Anal pain | 7.1% |  |

*Abbreviations:* CapeOx = capecitabine and oxaliplatin; RT = radiotherapy.

There were no grade 5 adverse events or treatment-related deaths.